Retrieve available abstracts of 63 articles: HTML format
Single Articles
June 2025
BARRAUD S, Vacher S, Schiffler C, Wong J, et al Genomic landscape of estrogen receptor-positive HER2-negative advanced breast
cancer with acquired resistance to aromatase inhibitors: Identification of an
ESR1 alteration-related gene signature.
Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03083. PubMedAbstract available
SCOTT OW, Tin Tin S, Cavadino A, Elwood JM, et al Statin use and breast cancer-specific mortality and recurrence: a systematic
review and meta-analysis including the role of immortal time bias and tumour
characteristics.
Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03070. PubMedAbstract available
May 2025
PIMENTEL-PARRA GA, Garcia-Vivar C, Escalada-Hernandez P, San Martin-Rodriguez L, et al Systematic review of clinical practice guidelines for long-term breast cancer
survivorship: assessment of quality and evidence-based recommendations.
Br J Cancer. 2025 May 17. doi: 10.1038/s41416-025-03059. PubMedAbstract available
TYRAKIS PA, Kampjut D, Steele GF, Lindstrom HJG, et al Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kalpha potently inhibits the
PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
Br J Cancer. 2025 May 13. doi: 10.1038/s41416-025-03035. PubMedAbstract available
KOTSOPOULOS J, Maxwell CA, Lubinski J, Huzarski T, et al Parity, breastfeeding, and the risk of early-onset breast cancer in women with a
BRCA1 pathogenic variant.
Br J Cancer. 2025 May 2. doi: 10.1038/s41416-025-03029. PubMedAbstract available
ABUDULA M, Astuti Y, Raymant M, Sharma V, et al Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast
cancer via VISTA.
Br J Cancer. 2025 May 2. doi: 10.1038/s41416-025-03013. PubMedAbstract available
April 2025
PU Y, Xu F, He A, Li R, et al Repurposing chlorpromazine for the treatment of triple-negative breast cancer
growth and metastasis based on modulation of mitochondria-mediated apoptosis and
autophagy/mitophagy.
Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02992. PubMedAbstract available
PETERS J, van Leeuwen MM, Moriakov N, van Dijck JAAM, et al Development of radiomics-based models on mammograms with mass lesions to predict
prognostically relevant characteristics of invasive breast cancer in a screening
cohort.
Br J Cancer. 2025 Apr 6. doi: 10.1038/s41416-025-02995. PubMedAbstract available
BUIJS SM, Jongbloed EM, van Bergen LEM, Ramakers CRB, et al Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.
Br J Cancer. 2025;132:525-532. PubMedAbstract available
March 2025
CAIAZZA F, McGowan PM, Mullooly M, Murray A, et al Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has
antitumour effects in triple-negative breast cancer cells.
Br J Cancer. 2025 Mar 14. doi: 10.1038/s41416-025-02973. PubMed
SKRIVER C, Cronin-Fenton D, Borgquist S, Hansen Viuff J, et al Statin use and risk of breast cancer among women with benign breast disease: a
Danish nationwide cohort study.
Br J Cancer. 2025 Mar 8. doi: 10.1038/s41416-025-02974. PubMedAbstract available
STEINDL A, Zach C, Berchtold L, Grisold A, et al Prognostic relevance of the neurological symptom burden in brain metastases from
breast cancer.
Br J Cancer. 2025 Mar 1. doi: 10.1038/s41416-025-02967. PubMedAbstract available
February 2025
ELLIOTT H, Allen AJ, Forester ND, Graziadio S, et al Women's perspectives of molecular breast imaging: a qualitative study.
Br J Cancer. 2025;132:276-282. PubMedAbstract available
January 2025
VILLETTE CC, Dupuy N, Brightman FA, Zimmermann A, et al Semi-mechanistic efficacy model for PARP + ATR inhibitors-application to
rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs.
Br J Cancer. 2025 Jan 28. doi: 10.1038/s41416-024-02935. PubMedAbstract available
December 2024
WU X, Ling Y, Zhang S, Zhang B, et al Advancing radiomics from contrast-enhanced mammography in breast cancer.
Br J Cancer. 2024 Dec 12. doi: 10.1038/s41416-024-02932. PubMed
WANG Q, Yu Y, Wang C, Jiang Z, et al Heterogeneity of tertiary lymphoid structures predicts the response to
neoadjuvant therapy and immune microenvironment characteristics in
triple-negative breast cancer.
Br J Cancer. 2024 Dec 10. doi: 10.1038/s41416-024-02917. PubMedAbstract available
November 2024
WANG W, Wang X, Jiang Y, Guo Y, et al Normal weight obesity, circulating biomarkers and risk of breast cancer: a
prospective cohort study and meta-analysis.
Br J Cancer. 2024 Nov 28. doi: 10.1038/s41416-024-02906. PubMedAbstract available
LUIJENDIJK MJ, Buijs SM, Jager A, Koolen SLW, et al Effects of tamoxifen on cognitive function in patients with primary breast
cancer.
Br J Cancer. 2024 Nov 26. doi: 10.1038/s41416-024-02914. PubMedAbstract available
GIRITHAR HN, Krishnamurthy S, Carroll L, Guller A, et al Breast cancer metastasis progression is associated with elevated activity of
kynurenine monooxygenase and kynureninase.
Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02889. PubMedAbstract available
SUN Y, Huo D Understanding genetic architecture of breast cancer: how can proteome-wide
association studies contribute?
Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02905. PubMed
TRAN TXM, Chang Y, Choi HR, Kwon R, et al Correction: Height and breast cancer risk in premenopausal Korean women aged
under 40 years of age.
Br J Cancer. 2024 Nov 11. doi: 10.1038/s41416-024-02886. PubMed
KAUFMANN M, Vaysse PM, Savage A, Kooreman LFS, et al Testing of rapid evaporative mass spectrometry for histological tissue
classification and molecular diagnostics in a multi-site study.
Br J Cancer. 2024;131:1298-1308. PubMedAbstract available
TORR B, Jones C, Kavanaugh G, Hamill M, et al BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK
breast oncology setting: a randomised, non-inferiority trial.
Br J Cancer. 2024;131:1506-1515. PubMedAbstract available
WANG S, Wang T, Guo S, Zhu S, et al Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in
differentiating HER2 expression status of invasive breast cancers: A
double-centre pilot study.
Br J Cancer. 2024;131:1613-1622. PubMedAbstract available
October 2024
ZHAO T, Xu S, Ping J, Jia G, et al A proteome-wide association study identifies putative causal proteins for breast
cancer risk.
Br J Cancer. 2024 Oct 28. doi: 10.1038/s41416-024-02879. PubMedAbstract available
EGELAND EV, Seip K, Skourti E, Oy GF, et al The SRC-family serves as a therapeutic target in triple negative breast cancer
with acquired resistance to chemotherapy.
Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02875. PubMedAbstract available
TRAN TXM, Chang Y, Choi HR, Kwon R, et al Height and breast cancer risk in premenopausal Korean women aged under 40 years
of age.
Br J Cancer. 2024 Oct 7. doi: 10.1038/s41416-024-02846. PubMedAbstract available
SABLIN MP, Gestraud P, Jonas SF, Lamy C, et al Copy number alterations in metastatic and early breast tumours: prognostic and
acquired biomarkers of resistance to CDK4/6 inhibitors.
Br J Cancer. 2024;131:1060-1067. PubMedAbstract available
CHIGUCHI G, Cho H What kind of tumour rupture requires adjuvant therapy?
Br J Cancer. 2024;131:1109-1110. PubMed
September 2024
CASTRO-ESPIN C, Cairat M, Navionis AS, Dahm CC, et al Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast
cancer survival: evidence from the EPIC cohort study.
Br J Cancer. 2024 Sep 28. doi: 10.1038/s41416-024-02858. PubMedAbstract available
PRASAD D, Baldelli E, Blais EM, Davis J, et al Functional activation of the AKT-mTOR signalling axis in a real-world metastatic
breast cancer cohort.
Br J Cancer. 2024 Sep 25. doi: 10.1038/s41416-024-02852. PubMedAbstract available
PHILLIPS JB, Park SS, Lin CH, Cho J, et al SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in
breast cancer.
Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02853. PubMedAbstract available
JAVED SR, Skolariki A, Zameer MZ, Lord SR, et al Implications of obesity and insulin resistance for the treatment of oestrogen
receptor-positive breast cancer.
Br J Cancer. 2024 Sep 9. doi: 10.1038/s41416-024-02833. PubMedAbstract available
O'LEARY RL, Duijm LEM, Boersma LJ, van der Sangen MJC, et al Invasive recurrence after breast conserving treatment of ductal carcinoma in situ
of the breast in the Netherlands: time trends and the association with tumour
grade.
Br J Cancer. 2024;131:852-859. PubMedAbstract available
KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al PARP inhibition with rucaparib alone followed by combination with atezolizumab:
Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative
breast cancers.
Br J Cancer. 2024;131:820-831. PubMedAbstract available
GRAFINGER OR, Hayward JJ, Meng Y, Geddes-McAlister J, et al Cancer cell extravasation requires (i)plectin-mediated delivery of MT1-MMP at
invadopodia.
Br J Cancer. 2024;131:931-943. PubMedAbstract available
August 2024
ARUN B, Couch FJ, Abraham J, Tung N, et al BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits
of genetic testing.
Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02827. PubMedAbstract available
ZOU R, Loke SY, Tang YC, Too HP, et al Correction: Development and validation of a circulating microRNA panel for the
early detection of breast cancer.
Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02800. PubMed
JOHNSON N, Bentley J, Wang LZ, Newell DR, et al Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent
kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer
cells.
Br J Cancer. 2024 Aug 19. doi: 10.1038/s41416-024-02813. PubMed
YUAN J, Xiao M, Zheng Q Comment on: "A nationwide study of breast reconstruction after mastectomy in
patients with breast cancer receiving postmastectomy radiotherapy: comparison of
complications according to radiotherapy fractionation and reconstruction
procedures".
Br J Cancer. 2024 Aug 1. doi: 10.1038/s41416-024-02807. PubMed
July 2024
LOHFELD L, Sharma M, Bennett D, Gavin A, et al Correction: Impact of the COVID-19 pandemic on breast cancer patient pathways and
outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02791. PubMed
BESSE A, Sedlarikova L, Buechler L, Kraus M, et al HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative
breast cancer.
Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02774. PubMedAbstract available
YAGHJYAN L, Heng YJ, Baker GM, Murthy D, et al Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast
density in women with benign breast biopsies.
Br J Cancer. 2024;131:325-333. PubMedAbstract available
June 2024
POSSENTI I, Scala M, Carreras G, Bagnardi V, et al Exposure to second-hand smoke and breast cancer risk in non-smoking women: a
comprehensive systematic review and meta-analysis.
Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02732. PubMedAbstract available
BOMAN C, Liu X, Eriksson Bergman L, Sun W, et al A population-based study on trajectories of HER2 status during neoadjuvant
chemotherapy for early breast cancer and metastatic progression.
Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02777. PubMedAbstract available
ZHU T, Huang YH, Li W, Wu CG, et al A non-invasive artificial intelligence model for identifying axillary
pathological complete response to neoadjuvant chemotherapy in breast cancer: a
secondary analysis to multicenter clinical trial.
Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02726. PubMedAbstract available
POUMEAUD F, Morisseau M, Cabel L, Goncalves A, et al Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab
Deruxtecan in HER2-low metastatic breast cancer.
Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02766. PubMedAbstract available
ZUO W, Wang Z, Qian J, Ma X, et al QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and
docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or
locally advanced breast cancer: A multicenter, randomized, double-blinded,
parallel-controll
Br J Cancer. 2024 Jun 21. doi: 10.1038/s41416-024-02751. PubMedAbstract available
RYU H, Shin KH, Chang JH, Jang BS, et al A nationwide study of breast reconstruction after mastectomy in patients with
breast cancer receiving postmastectomy radiotherapy: comparison of complications
according to radiotherapy fractionation and reconstruction procedures.
Br J Cancer. 2024 Jun 5. doi: 10.1038/s41416-024-02741. PubMedAbstract available
TSOULAKI O, Tischkowitz M, Antoniou AC, Musgrave H, et al Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical
practice.
Br J Cancer. 2024;130:2027-2036. PubMedAbstract available
May 2024
TREEKITKARNMONGKOL W, Shah V, Kai K, Katayama H, et al Epigenetic activation of SOX11 is associated with recurrence and progression of
ductal carcinoma in situ to invasive breast cancer.
Br J Cancer. 2024 May 17. doi: 10.1038/s41416-024-02697. PubMedAbstract available
HAM B, Kim SY, Kim YA, Han D, et al Persistence and enrichment of dominant T cell clonotypes in expanded
tumor-infiltrating lymphocytes of breast cancer.
Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02707. PubMedAbstract available
STOER NC, Vangen S, Singh D, Fortner RT, et al Menopausal hormone therapy and breast cancer risk: a population-based cohort
study of 1.3 million women in Norway.
Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590. PubMedAbstract available
LOHFELD L, Sharma M, Bennett D, Gavin A, et al Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in
the United Kingdom and the Republic of Ireland - a scoping review.
Br J Cancer. 2024 May 4. doi: 10.1038/s41416-024-02703. PubMedAbstract available
SHEN F, Jiang G, Philips S, Cantor E, et al Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN
5103 and BEATRICE.
Br J Cancer. 2024;130:1348-1355. PubMedAbstract available
NG CW, Tsang YTM, Gershenson DM, Wong KK, et al The prognostic value of MEK pathway-associated estrogen receptor signaling
activity for female cancers.
Br J Cancer. 2024;130:1875-1884. PubMedAbstract available
April 2024
HANNA D, Merrick S, Ghose A, Devlin MJ, et al Real world study of sacituzumab govitecan in metastatic triple-negative breast
cancer in the United Kingdom.
Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02685. PubMedAbstract available
CHANG CY, Jones BL, Hincapie-Castillo JM, Park H, et al Association between trajectories of adherence to endocrine therapy and risk of
treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
Br J Cancer. 2024 Apr 18. doi: 10.1038/s41416-024-02680. PubMedAbstract available
BRAUN M, Piasecka D, Sadej R, Romanska HM, et al FGFR4-driven plasticity in breast cancer progression and resistance to therapy.
Br J Cancer. 2024 Apr 17. doi: 10.1038/s41416-024-02658. PubMedAbstract available
ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al Neratinib could be effective as monotherapy or in combination with trastuzumab in
HER2-low breast cancer cells and organoid models.
Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665. PubMedAbstract available
ALEXANDER J, Schipper K, Nash S, Brough R, et al Pathway-based signatures predict patient outcome, chemotherapy benefit and
synthetic lethal dependencies in invasive lobular breast cancer.
Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679. PubMedAbstract available
March 2024
LIU X, Cheng X, Xie F, Li K, et al Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and
tumour immunity in first-line HER2-positive metastatic breast cancer.
Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02610. PubMedAbstract available
TEN VELDE DE, Duijm LEM, van der Sangen MJC, Schipper RJ, et al Long-term trends in incidence, characteristics and prognosis of screen-detected
and interval cancers in women participating in the Dutch breast cancer screening
programme.
Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02633. PubMedAbstract available